NASDAQ · Biotechnology

ERAS (ERAS) Stock

$17.72 -2.42% NASDAQ: ERAS Healthcare

Valuation

MetricValue
Price$17.72
Market Cap$6.15B
P/E Ratio-23.45
P/B Ratio9.87
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$24.28
52-Week Low$1.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-38.46%
ROA-31.57%
ROCE-40.31%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.12
Current Ratio9.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-125.0M$-247.0M$-142.0M$-180.0M$-131.0M
Net Profit$-123.0M$-243.0M$-125.0M$-162.0M$-125.0M
EPS$-1.03$-1.99$-0.83$-0.69$-0.44
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$501.0M$515.0M$395.0M$503.0M$396.0M
Total Liabilities$45.0M$103.0M$79.0M$79.0M$71.0M
Cash$360.0M$284.0M$93.0M$68.0M$74.0M
Borrowings$19.0M$55.0M$56.0M$52.0M$47.0M

Latest News

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns Simply Wall St. · Jul 16, 2026 Erasca Closes $632.5 Million Upsized Common Stock Offering MT Newswires · Jul 15, 2026 Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Jul 15, 2026 Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full? Simply Wall St. · Jul 15, 2026 Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers Simply Wall St. · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-80.0M$-103.0M$-101.0M$-109.0M$-95.0M
Investing Cash Flow$-83.0M$-88.0M$-93.0M$-179.0M$100.0M
Financing Cash Flow$3.0M$3.0M$0$2.0M$0
Net Cash Flow$295.0M$-76.0M$-191.0M$-25.0M$6.0M
Free Cash Flow$-98.0M$-120.0M$-103.0M$-132.0M$-96.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-2.85%
Quick Ratio9.52
Interest Coverage—
Return 1Y1192.00%
Return 3Y636.88%
Return 5Y-3.10%

Ownership

Insiders Held10.66%
Institutions Held93.59%
Institutions Float Held104.75%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 24,675,1882026-03-31
T. Rowe Price Investment Management, Inc.21,259,6462026-03-31
Blackrock Inc.20,151,4062026-03-31
Venrock Adviser, LLC16,382,8122026-03-31
RTW Investments LP16,157,1752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
CTMX $3.37 +4.01% -24.27 $541.98M 0.00%

About ERAS

ERAS is led by CEO Jonathan E. Lim, employs 103 people, headquartered in San Diego, US, publicly traded since 2021.

ERAS stock trades at $17.72 with a market capitalization of $6.15B. The stock is valued at a price-to-earnings (P/E) ratio of -23.45, price-to-book of 9.87, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.21 and $24.28, and currently trades 27.0% below its 52-week high.

On profitability, ERAS generates a return on equity (ROE) of -38.46%, return on capital employed of -40.31%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides